Q&A with Dr. Bruce Liang, dean of the UConn School of Medicine
This time last year you launched the new MDelta curriculum. How has it gone?
Despite the enormous amount of work, change, and adjustment it takes to change a curriculum, it has gone smoothly and the feedback is validating all the reasons for this change. I believe we are now built to continue to deliver an excellent education to meet the explosive expansion in science and clinical knowledge, and the timing is perfect, as medical school enrollment continues to grow.
Describe how the faculty has grown and how that strengthens the UConn School of Medicine.
Faculty recruitment and retention is a central part of my agenda to make sure the School of Medicine is, and remains, strong. I’m pleased that we have hired 280 faculty members in the last five years, growing from 421 to 542, with a net increase of 121 new faculty. That’s a tremendous amount of new energy, expertise, and possibilities to keep the school, and UConn Health, on the rise. That shows in our U. S. News and World Report rankings, where we rose to 56th in research and 34th in the primary care categories among 170 accredited medical schools in the country.
In what ways is the Bioscience Connecticut investment paying off for the School?
Progress is everywhere as we work to deliver on the aspirations of the investment. We have begun to expand class sizes in the medical school and draw more talented graduate students pursuing advanced or terminal degrees, who will develop into the doctors and scientists serving Connecticut in the future.
Research expenditures, funded by grants, contracts, and gifts, have approached nearly $90 million annually, helping us attract and retain talent and increasing the biomedical science jobs available here. We are already seeing a bioscience hub take form right here in Farmington, where our Technology Incubation Program is 70 percent full, housing 24 start-up companies, of which 15 are linked to UConn Health and the faculty.
A centerpiece of the bioscience project was bringing the Jackson Laboratory to Farmington as a collaborator. What has that relationship meant for UConn School of Medicine’s academic and research objectives?
The relationship has grown in the last three years to the mutual benefit of UConn Health and the Jackson Laboratory for Genomic Medicine (JAX-GM). However, the collaboration is young and will grow in ways none of us today can imagine. JAX-GM already has exceeded the 10-year, 300-job benchmark, and together we have hired five new joint faculty members, with five more planned. In addition, nearly 20 JAX-GM faculty members have joint appointments at the School. Our existing faculty and new JAX-GM faculty have worked together to secure grant funding. This opens a door to academic and research collaboration in new and interesting ways.
This past summer, together we hosted the International Congress on Ethical, Legal, and Social Issues in Genomics on the UConn Health campus. Our faculty and those at JAX came together with the brightest minds and thought leaders from around the world to share, learn, and advance genomics. That kind of opportunity for our students and faculty, and exposure for Connecticut on the world stage, cannot be overstated for its long-term impact to the school and the University.